Business Context and Reporting Period
This Form 8-K was filed by Biorestorative Therapies, Inc. on December 12, 2019, reporting events occurring between December 9, 2019, and December 18, 2019. The company is an emerging growth company incorporated in Delaware with principal executive offices in Melville, New York. The filing details unregistered sales of equity securities and the issuance of a convertible promissory note.
Key Financial Metrics and Capital Structure
- Debt-for-Equity Exchange: The company issued 13,091,685 shares of common stock to settle outstanding indebtedness totaling $136,651, inclusive of accrued and unpaid interest.
- New Debt Issuance: On December 18, 2019, the company issued a convertible promissory note with a principal amount of $115,500, receiving cash proceeds of $100,000.
- Note Terms: The new note bears interest at 12% per annum, matures in December 2020, and is convertible into common stock at $1.00 per share for the first six months, thereafter at 58% of the fair value of the common stock.
- Liquidity and Margins: The filing text does not provide clear values for revenue, profit, operating cash flow, or profit margins.
Material Changes
The primary material change reported is the significant increase in outstanding common shares due to the conversion of $136,651 in debt. Additionally, the company's debt load increased by $115,500 in principal, though this was partially offset by the debt extinguishment. The filing does not provide comparative financial data for prior periods to quantify percentage changes in overall financial position.
Guidance, Risks, and Unusual Items
- Regulatory Compliance: The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for exemptions from registration, asserting that no general solicitation was used and investors were accredited.
- Investor Access: Investors were provided access to the Company's 2018 Form 10-K, 2019 quarterly Forms 10-Q, and prior 8-K filings.
- Unusual Items: The issuance of a large volume of shares (over 13 million) for a relatively small debt amount ($136,651) suggests a low valuation per share at the time of the exchange.
- Outlook: The filing contains no forward-looking guidance or management commentary regarding future business operations or financial projections.
Investor Verification Checklist
- Verify the current share count and the dilution impact of the 13,091,685 newly issued shares.
- Confirm the fair value of the common stock used to calculate the conversion price for the new convertible note after the initial six-month period.
- Review the company's cash position to assess the ability to service the new $115,500 note and the 12% interest obligation.
- Examine the 2018 Form 10-K and 2019 Forms 10-Q referenced in the filing to understand the full scope of the company's financial health and prior indebtedness.